Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer
Interventions: BIOLOGICAL: GB221,2 mg/kg|BIOLOGICAL: GB221,6 mg/kg|BIOLOGICAL: Herceptin,6 mg/kg|BIOLOGICAL: GB221,8mg/kg|BIOLOGICAL: GB221:2mg/kg and Capecitabi:1000mg/kg|BIOLOGICAL: Herceptin:2mg/kg and Capecitabin:1000mg/kg
Sponsor: Genor Biopharma Co., Ltd.